Product Overview
CJC-1295 (No DAC) | 2mg, 5mg & 10mg
CJC-1295 (No DAC), scientifically classified as Modified GRF 1-29, is a synthetic analogue of Growth Hormone Releasing Hormone (GHRH).
It is critical for researchers to distinguish this peptide from both standard Sermorelin (GRF 1-29) and CJC-1295 with DAC.
Vs. Sermorelin: This peptide has been chemically altered with four specific amino acid substitutions (Tetrasubstitution). These changes protect the peptide from rapid cleavage by the enzyme DPP-IV, extending its biological half-life from ~5 minutes (Sermorelin) to ~30 minutes. Vs. CJC-1295 DAC: This version lacks the Drug Affinity Complex (DAC). This means it does not bind to serum albumin for days. Instead, it provides a strictly pulsatile release of Growth Hormone that mimics the body's natural circadian rhythm.
This specific pharmacokinetic profile makes CJC-1295 (No DAC) the gold-standard reagent for investigating physiologic, pulsatile GH secretion without the risk of "GH bleed" or pituitary desensitisation often observed with long-acting DAC variants.
Technical Specifications
Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2 Chemical Name: Modified GRF 1-29 / Tetrasubstituted GRF 1-29 Format: Lyophilised Cake/Powder Purity: >99% (HPLC Verified) Half-Life: Approx. 30 minutes (Extended vs. Native GHRH) Solubility: High (Aqueous) Solvent: Solvent not included (Sold Separately) Grade: Analytical Research Grade
Variant Breakdown
2mg & 5mg Vials: Standard research aliquots. 10mg Vial: High-Concentration Vial.
Note: All variants are contained within a 3ml capacity vial.
Quality Assurance
This compound has undergone rigorous third-party analysis.
HPLC Verified: Independent analysis confirms peptide purity exceeds 99%. Mass Spectrometry: Confirms the presence of the four amino acid substitutions that define "Mod GRF." TFA Removal: Processed via acetate exchange to ensure high viability in sensitive cell culture applications.
Research Mechanism
In laboratory settings, CJC-1295 (No DAC) is utilised to investigate:
Pulsatile Signaling: How short-acting GHRH analogues amplify the natural peaks of GH secretion when timed with endogenous somatostatin inhibition. Synergy Studies: It is frequently used in combination with GHRPs (like Ipamorelin or GHRP-6) to study the synergistic "multiplier effect" on pituitary somatotrophs. Sleep Architecture: Researching the impact of amplified GH pulses on Slow Wave Sleep (SWS) and recovery cycles in animal models.
Safety and Handling
WARNING: This product is exclusively for laboratory research and in vitro use.
Research Only: Not intended for human consumption, bodybuilding, or therapeutic use. Handling: Wear appropriate personal protective equipment (PPE).
Storage: Store lyophilised vials in a cool, dry place. For long-term preservation, freezing at -20°C is recommended.
Scientific References
Journal of Clinical Endocrinology & Metabolism (2006) – "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295." (The seminal paper comparing DAC vs No DAC pharmacokinetics). View Article
Drug Design, Development and Therapy (2015) – "Growth hormone-releasing hormone (GHRH) and its analogues: a review." View Article
Peptides (2002) – "Stability of GRF(1-29)NH2 in solution: effect of pH and temperature." (Referencing the stability issues that Mod GRF 1-29 was designed to solve). View Article
Neuroendocrinology (1995) – "Growth hormone-releasing hormone and growth hormone secretagogues in normal aging." View Article